Evidence map›Paper›PMID 41702895›Full record

ArticleSignal transduction and targeted therapy2026

Exogenous Epstein-Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy.

Changlin Liu, Zhiqiang Sun, Chao Li, Yanqing Zhou, Xuefeng Gao, Yuping Zhong, Xiaomin Luo, Chenci Wang, Yuanbin Zhang, Chuping Ni and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Changlin Liu *Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Zhiqiang Sun *School of Pharmaceutical Science, Southern Medical University, Guangdong, China.
Chao Li *Department of Oncology, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yanqing Zhou *Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Xuefeng Gao *Shenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Yuping ZhongDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital, Shenzhen, Guangdong, China.
Xiaomin LuoShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.ORCID http://orcid.org/0000-0002-2334-6544
Chenci WangDepartment of Oncology, Funan County People's Hospital, Fuyang, Anhui, China.
Yuanbin ZhangShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Chuping NiShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Manli PengShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Weiquan JianShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Yinggui YangShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China.
Xuewen ZhangSchool of Pharmaceutical Science, Southern Medical University, Guangdong, China.
Yichang RenSchool of Pharmaceutical Science, Southern Medical University, Guangdong, China.
Xinqi GongMathematical Intelligence Application LAB, Institute for Mathematical Sciences, Renmin University of China, Beijing, China.
Min ZhaoPANACRO (Hefei) Pharmaceutical Technology Co. Ltd., Hefei, China.
Xia GuoShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China. myshow0504@smu.edu.cn.
Chao ChengDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital, Shenzhen, Guangdong, China. nurswan@126.com.
Jianjun ChenSchool of Pharmaceutical Science, Southern Medical University, Guangdong, China. jchen21@smu.edu.cn.ORCID http://orcid.org/0000-0001-5668-6572
Xin LiShenzhen Key Laboratory of Viral Oncology, Shenzhen Hospital of Southern Medical University, Guangdong, China. lixin@smu.edu.cn.

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273134National Natural Science Foundation of China (National Science Foundation of China) 82472797National Natural Science Foundation of China (National Science Foundation of China) 82503331
6 · The paper itself

Abstract

Immune checkpoint blockade (ICB) therapy continues to face limitations due to tumor resistance linked to suppressed interferon (IFN) signaling. This suppression can be attributed to multiple mechanisms, among which viral pathogens represent a compelling though not yet fully elucidated factor. Here, we demonstrate that exogenous Epstein-Barr virus-encoded EBNA1 drives immunosuppression via enhanced RNA-editing enzyme ADAR1-mediated RNA editing. Comparative tumor model analyses revealed that EBNA1 overexpression reduced CD8

Indexed as

Adenosine DeaminaseEpstein-Barr Virus Nuclear AntigensImmunotherapyNeoplasmsRNA-Binding ProteinsAnimalsCD8-Positive T-LymphocytesCell Line, TumorHerpesvirus 4, HumanHumansMiceProteolysis Targeting ChimeraRNA EditingADAR protein, humanAdenosine DeaminaseEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensProteolysis Targeting ChimeraRNA-Binding Proteins

Identifiers

PMID41702895
PMCPMC12913968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.